Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Stocks
Currencies
Cryptocurrencies
Metals
Indices
Commodities
ETFs
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
News
Top Providers News
Top Providers News
Symbols
Market
Provider
Time
Symbols
News
Provider
2026.11.10
Goldman Sachs Maintains Sell on H&R Block, Raises Price Target to $40
Benzinga
2026.11.10
BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In Cash
Benzinga
2026.11.10
Redwire Selected For ~$40M Award To Provide Integrated Power Generation System To Support NASA’s Pioneering Moon Base Efforts
Benzinga
2026.11.10
PepGen Announces Data From Its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 Demonstrates Mean Splicing Correction Of 46.5%; PGN-EDODM1 Showed High Tolerance;
Benzinga
2026.11.10
Urban One Q3 EPS $(26.39) Down From $(0.60) YoY, Sales $88.005M Down From $92.677M YoY
Benzinga
2026.11.10
Hemab Therapeutics Hldgs Q3 EPS $(0.58) Misses $(0.52) Estimate
Benzinga
2026.11.10
Xanadu Quantum Technologies And Thin-Film Lithium Niobate Photonics Maker HyperLight Announce Hardware Performance Milestone Of Reducing Optical Switch Insertion Loss To 7mdB
Benzinga
2026.11.10
11 Communication Services Stocks Moving In Tuesday's Pre-Market Session
Benzinga
2026.11.10
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga
2026.11.10
12 Industrials Stocks Moving In Tuesday's Pre-Market Session
Benzinga
2026.11.10
12 Information Technology Stocks Moving In Tuesday's Pre-Market Session
Benzinga
2026.11.10
908 Devices Q3 EPS $(0.11) Beats $(0.17) Estimate, Sales $18.950M Beat $18.300M Estimate
Benzinga
2026.11.10
Harvard Bioscience Raises FY2026 Sales Guidance from $88.281M-$90.012M to $89.147M-$90.877M vs $89.794M Est
Benzinga
2026.11.10
City Therapeutic Doses First Patient In Its Clinical Study Of CITY-RBP4 To Treat Stargardt Disease Type 1
Benzinga
2026.11.10
Harvard Bioscience Sees Q4 Sales $23.700M-$25.500M vs $24.500M Est
Benzinga
2026.11.10
Bitdeer Technologies Q3 Adj. EPS $(0.38) Misses $(0.34) Estimate, Sales $320.700M Beat $256.286M Estimate
Benzinga
2026.11.10
Gilat Satellite Networks Lowers FY2026 Sales Guidance from $500.000M-$520.000M to $455.000M-$475.000M vs $507.063M Est
Benzinga
2026.11.10
Palladyne AI Raises FY2026 Sales Guidance from $24.000M-$27.000M to $25.000M-$27.000M vs $24.849M Est
Benzinga
2026.11.10
Humacyte Q3 EPS $(0.06) Beats $(0.08) Estimate, Sales $1.028M Beat $766.000K Estimate
Benzinga
2026.11.10
Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M
Benzinga
2026.11.10
Cellectar Biosciences Q3 EPS $(0.46) Beats $(0.56) Estimate
Benzinga
2026.11.10
Chicago Atlantic Real Q3 Adj. EPS $0.49 Beats $0.42 Estimate, Sales $12.470M Miss $15.648M Estimate
Benzinga
2026.11.10
Scholar Rock Holding Q3 EPS $(0.81) Beats $(0.85) Estimate, Sales $600.000K Beat $22.429K Estimate
Benzinga
2026.11.10
Quarterhill Q3 EPS $(0.13) Misses $(0.04) Estimate, Sales $43.157M Miss $48.579M Estimate
Benzinga
2026.11.10
HC Wainwright & Co. Reiterates Buy on Senseonics Holdings, Maintains $14 Price Target
Benzinga
2026.11.10
Etoro Group Q3 Adj. EPS $0.26 Misses $0.35 Estimate, Sales $1.486B Beat $195.725M Estimate
Benzinga
2026.11.10
Legend Biotech Q3 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $359.500M Miss $361.619M Estimate
Benzinga
2026.11.10
Alliance Laundry Holdings Affirms FY2026 Sales Guidance of $1.812B-$1.829B vs $1.823B Est
Benzinga
2026.11.10
Autolus Therapeutics Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $41.238M Beat $39.537M Estimate
Benzinga
2026.11.10
908 Devices Raises FY2026 Sales Guidance from $68.000M-$70.000M to $68.500M-$70.000M vs $69.133M Est
Benzinga
1
...
122
123
124
125
126
127
...
712
>